| | HOUSTON, Dec. 3, 2019 /PRNewswire/ -- CNS PHARMACEUTICALS AG Inc. (NASDAQ: CNSP) a biotechnology company specializing in the development of novel treatments for brain tumors, today announced that John Climaco, Chief Executive Officer of CNS Pharmaceuticals, will be participating in the 12th Annual LD Micro Main Event Conference in Los Angeles, CA. | Event: | 12th Annual LD Micro Main Event Conference | | Format: | Presentation & 1x1 Meetings | | Date: | Tuesday, December 10, 2019 | | Time: | 4:20pm PT | | Location: | Luxe Sunset Boulevard Hotel, Los Angeles, CA | About Berubicin
Berubicin is an anthracycline, a class of drugs among the most powerful chemotherapy drugs and effective against more types of cancer than any other class of chemotherapeutic agents. Anthracyclines are designed to damage the DNA of targeted cancer cells by interfering with the action of the topoisomerase II, a critical enzyme enabling cell proliferation. Berubicin was developed at the MD Anderson Cancer Center (MDACC), the world’s largest cancer research facility. Berubicin appeared to demonstrate one Durable Complete Response in a Phase I human clinical trial conducted by a prior developer. About CNS Pharmaceuticals Inc.
CNS Pharmaceuticals is a biotechnology company specializing in the development of novel treatments for primary and metastatic brain and central nervous system tumors. Its lead candidate Berubicin is for the treatment of glioblastoma, a type of brain cancer currently considered incurable, as well as pancreatic and ovarian cancers, and lymphomas. The Company entered into an IP agreement with Houston Pharmaceuticals, Inc. and a Purchase Agreement with Reata Pharmaceuticals Inc. For more information, visit www.cnspharma.com  View original content:http://www.prnewswire.com/news-releases/cns-pharmaceuticals-to-participate-in-12th-annual-ld-micro-main-event-conference-300967894.html
SOURCE CNS Pharmaceuticals, Inc. | |
